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Abstract  
Systemic sclerosis (SSc) is associated with high mortality owing to internal organ complications and lung 
disease is the leading cause of SSc-associated death. The most notable lung complications in SSc are 
fibrosis and pulmonary arterial hypertension (PAH). A major challenge for the management of lung 
disease in SSc is detecting those patients with severe pathology and those patients that are likely to 
benefit from available treatments. In the past few, strategies for managing lung fibrosis and pulmonary 
hypertension, including PAH, have greatly progressed. For lung fibrosis, the tools to assess risk of 
progression and severity of the disease have been refined. Clinical trial results support the use of 
immunosuppression, including high intensity regimens with autologous stem cell transplantation. New 
trials are underway to test other potential therapies including treatments that are approved for use in 
idiopathic lung fibrosis. For PAH, identifying individuals at high risk of disease development is critical. In 
addition, individuals who have borderline elevation of pulmonary arterial pressure need to be 
appropriately managed and followed up. Many approved drugs targeting PAH are now available and 
results from large-scale clinical trials provide robust evidence that various treatments for SSc-associated 
PAH are associated with good long-term outcomes.  
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[H1] Introduction  
Systemic sclerosis (SSc) is an uncommon disease characterized by fibrosis of the skin and internal organs 
and by vasculopathy. Amongst the autoimmune rheumatic diseases, systemic sclerosis has the highest 
mortality, which is mainly owing to the development of complications that affect the lungs [1,2]. The 
two most important lung complications in SSc are lung fibrosis, which reflects the tendency of SSc to 
cause scarring in the skin and internal organs, and pulmonary arterial hypertension (PAH), which reflects 
the cardinal proliferative vasculopathy that occurs in SSc [3,4]. SSc can be divided into two major clinical 
subsets on the basis of the extent of skin fibrosis: limited cutaneous SSc (lcSSc, affecting the face, neck 
and distal limbs) and diffuse cutaneous SSc (dcSSc, affecting the proximal limbs, abdomen and chest). 
These two major subsets also differ in the associated frequency and pattern of different SSc-associated 
autoantibodies and cardinal clinical characteristics [5].  
The pathogenic mechanisms of lung fibrosis and pulmonary arterial hypertension are complex and 
incompletely understood but involve an interplay and cross talk between the cellular constituents of the 
lung. These complications are probably triggered by lung injury or damage in the epithelial and 
parenchymal compartments (for lung fibrosis) or the endothelium and pulmonary vasculature (for 
pulmonary hypertension) (Figure 1).  Strategies for managing lung fibrosis and pulmonary hypertension, 
especially PAH, have considerably advanced in the past few years. Major challenges in managing both 
conditions include the detection of patients with clinically meaningful disease, the identification of 
patients who are likely to benefit from intervention and the formulation of an optimal management plan 
that includes the treatment goals, the choice and dose of treatments and the means for efficiently 
monitoring patients. 
With regard to lung fibrosis, new developments in our understanding of the pathogenesis have led to 
pivotal clinical trials of historical treatments and novel therapies. The search continues for treatments 
that might be as effective but are safer than current therapies. Several targeted biological therapies are 
being tested as one possible avenue. Likewise, the development of antifibrotic agents has made 
substantial progress. In addition, researchers are defining new tools for assessing the severity of lung 
fibrosis in SSc and the risk of progression, which should help improve the accuracy of treatment 
decisions.  
In pulmonary hypertension, detecting patients with SSc at high risk of developing PAH, as well as 
differentiating patients with PAH from patients with other forms of pulmonary hypertension (including 
post-capillary disease), is challenging. Once a patient is diagnosed with PAH, the effects of relevant co-
morbidities including other lung or heart complications on the patient’s disease are important to 
consider.  
  The publication of the results of new clinical trials into the treatment of lung complications in SSc have 
advanced practice and provide an evidence base to support current treatments. For both lung fibrosis 
and PAH, the concept of improving established disease and not just slowing progression is advancing. In 
this Review, we cover the major pulmonary aspects of SSc and discuss the current diagnostic approaches 
and treatment strategies.  
[H1] Pathogenesis  
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Lung involvement in systemic sclerosis is best defined in terms of extrapulmonary features such as 
respiratory muscle weakness or skin fibrosis of the chest wall that might restrict breathing and includes 
pleural effusion, and intrapulmonary manifestations. The two major complications within the lung are 
lung fibrosis and pulmonary hypertension although other processes involving the lung parenchyma can 
also develop.  Other less common forms of parenchymal disease such as organizing pneumonia. 
Pulmonary vascular disease includes pulmonary arterial hypertension (PAH) and other forms of 
pulmonary vasculopathy such as thromboembolic disease and pulmonary veno-occlusive disease. These 
forms of pulmonary vasculopathy should be distinguished from post-capillary pulmonary hypertension. 
These various lung complications can have shared underlying disease mechanisms (Figure 1).  
[H2] Pathogenesis of lung fibrosis 
Fibrosis is a general term describing the excessive formation of scarred or thickened tissue with 
excessive extracellular matrix in response to tissue damage, inflammation or as part of a specific process 
termed fibrogenesis in which activated fibroblasts or myofibroblasts produce excessive extracellular 
matrix. SSc-associated lung fibrosis probably shares common pathogenic mechanisms with other 
parenchymal lung diseases and with other manifestations of SSc. Multiple cell types and mediators are 
implicated in lung fibrogenesis [6,7], including lung epithelial cells (pneumocytes), inflammatory cells of 
all immune lineages and mesenchymal cells (including lung fibroblasts and myofibroblasts) [29,30]. 
Myofibroblasts are activated profibrotic contractile cells that resemble fibroblasts but are characterized 
by the expression of α-smooth muscle actin; myofibroblasts are central to the development of fibrotic 
lung pathology (Figure 1).  
Some clues about SSc pathogenesis have emerged from gene expression profiling studies of lung tissue 
and cultured fibroblasts [8,9] as well as of other cells isolated from biopsy samples or obtained through 
broncho-alveolar lavage [10] including lymphocytes, mononuclear cells and fibrocytes. Functional 
studies have confirmed that lung fibroblasts have a profibrotic phenotype in SSc [11] and researchers 
have identified candidate pathways and regulators, including TGF, CCL2 and IL13 that enhance 
extracellular matrix production and increase contractility and myofibroblast differentiation [12,13,14]. 
Studies of epithelial and endothelial cells from the lung tissue of patients with SSc-associated lung 
fibrosis also suggest a role for endothelial–mesenchymal and epithelial–mesenchymal transition in 
fibrotic lung pathology [15,16], meaning that the pathogenic population of myofibroblasts has multiple 
potential lineages of origin that might contribute to excessive extracellular matrix deposition and 
obliteration of normal lung architecture. In addition, serum levels of IL-6, monocyte chemotactic protein 
1 (MCP1; also known as CCL2) and CXC-chemokine ligand 4 (CXCL4) are associated with the occurrence 
and/or progression of lung fibrosis in SSc, implicating these factors as potential markers or mediators of 
lung fibrosis. [17,18,19]  
As with other parenchymal lung diseases, environmental factors probably contribute to pathogenesis. In 
SSc, epithelial injury and damage resulting from aspiration or micro-aspiration are potentially involved in 
lung fibrogenesis. In one mouse strain, that is genetically susceptible to lung injury, the introduction of a 
mildly acidic saline solution into the lungs caused fibrosis [20]. This finding was consistent with human 
studies that have demonstrated the presence of epithelial injury (as measured by serum levels of Mucin-
1 (also known as KL-6) or clearance of aerosolized diethylenetriamine penta-acatate (DTPA) [21] in 
patients with SSc or have linked lung fibrosis severity with oesophageal reflux severity in SSc [22,23].  
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Epithelial injury might selectively activate profibrotic pathways including TGFsignalling pathways, 
possibly via promoting conformational changes in the integrin–TGF complex. The involvement of 
epithelial injury and defective repair in lung fibrogenesis via increased TGF pathway activation is 
supported by the results from several relevant mouse models [24,25] through local activation of TGF 
via integrin pathways or via post-natal activation of canonical receptor mediated signaling. . 
Experimental findings of genetically modified mice with fibroblast-specific attenuation of TGF signalling 
further support a pivotal role for TGF signalling in the development of lung fibrosis and explant 
fibroblast studies are supported by analysis of SSc lung tissue that includes multiple cell types that may 
interact in vivo.  A subpopulation of lung fibroblasts is speculated to co-ordinate repair and be involved 
in the regulation of fibrogenic cells from peripheral blood including fibrocytes [26,27]. Other lineages 
such as endothelial cells and lung epithelial cell lineages might also contribute to the fibrogenic 
population of cells in SSc. In the past few years, studies of mouse models have attempted to incorporate 
human tissue or have explored effect on human skin ex vivo.  These studies suggest that chronic 
administration of bleomycin may give more consistent results and support an important potential role 
for circulating fibrogenic cells [29,30]. 
Circulating and local resident monocyte–macrophage lineages are emerging as potential key effector 
cells in SSc lung fibrosis [16,31,32]. Analysis of genes expressed in the skin that are associated with 
severity of lung fibrosis [33] and a similar gene and protein analysis using a systems biology approach 
has contributed to a growing body of evidence implicating altered monocyte and macrophage function 
in the pathogenesis of SSc-associated lung fibrosis [34] based upon comparison of gene expression in 
different tissue substrates in SSc.  
Genetic susceptibility might also be important in the development of lung fibrosis. A strong and 
consistent association exists between genetic risk factors (such as those identified by Immunochip 
analysis) and ANA patterns, providing support for a key role for the adaptive immune response in SSc 
pathogenesis [35]. Many genetic studies have been undertaken in SSc-associated lung fibrosis and a 
growing number of candidates have been identified from association studies or direct sequencing [36, 
37,38,39]. In general, immunological or inflammatory candidates seem to be more consistently 
identified in independent cohorts than factors relating to fibrosis, although in a complex heterogeneous 
disease such as SSc, the genetic associations from single cohorts might shed light on candidate pathways 
or mediators involved in pathogenesis even if conventional genetic replications across cohorts is not 
possible. This heterogeneity might reflect gene–environment interactions, differences in cofactors and 
other genetic or epigenetic differences between different study cohorts. For example, the association of 
SSc and a polymorphism in CTGF was reported by two independent single center cohorts [40,41] but not 
in another large multi-national study population [43]. Findings from two meta-analyses support a role 
for this polymorphism in patients from UK or Japanese backgrounds but not other [42]s, which could 
explain previous negative results [43, 44]. Epigenetic factors are potential contributors to SSc 
fibrogenesis; for example, particular microRNAs, including miR-155, are associated with lung fibrosis [45] 
and bromodomain inhibitors having potential anti-fibrotic effects in SSc lung fibroblasts [46]. Additional 
complex gene-environment interactions likely contribute to lung pathology in SSc; for example, 
experimental studies support a role for the microbiome, with early antibiotic exposure associated with 
increased susceptibility to experimental lung fibrosis in a scleroderma mouse model [47]. 
[H2] Pathogenesis of pulmonary hypertension 
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The development of pulmonary hypertension in SSc and lung fibrosis have overlapping features. 
Vascular injury including pulmonary endothelial cell injury and endothelial dysfunction might be a key 
component in the development of both pathologies; vascular injury leads to an aberrant 
fibroproliferative or aberrant repair process that also results in an obliterative pulmonary vasculopathy 
[48]. SSc-associated PAH is histologically similar to idiopathic or hereditable PAH with muscularisation of 
intrapulmonary arterioles and medial thickening with perivascular inflammatory changes, although SSc-
associated PAH has a lower prevalence of endothelial proliferative and plexiform lesions than other 
forms of PAH [49]. SSc-associated PAH could even be a phenocopy of heritable PAH. The TGF receptor 
family member bone morphogenetic protein receptor type-2 (BMPR2) is implicated in the pathogenesis 
of a number of forms of PAH, notably hereditable disease and idiopathic PAH; reduced levels of BMPR2 
in the lung blood vessels is associated with structural changes in the lung [50]. Interestingly, mouse 
models of SSc that implicate endothelial injury as a trigger of SSc-associated PAH also point towards a 
possible defect in BMPRII expression and function that could represent a unifying mechanism and 
potential susceptibility factor for several forms of PAH [51]. Hence, SSc might be a susceptibility 
phenotype for PAH, which would explain why the risk of developing PAH is highest in established disease 
and continues through the course of follow up [52].  
The mechanisms of PAH are likely complex and as with lung fibrosis probably involve multiple cell 
compartments that might contribute differently in different patients. Support for the role of immune 
cells in the development of SSc-associated PAH is emerging; on the basis of transcriptomic and serum 
analysis, macrophage or monocyte dysfunction, including M2 polarization, is associated with PAH 
development in SSc [53]. Endothelial cell to mesenchymal transition might also contribute to the 
fibroproliferative pathology seen in affected pulmonary vessels [54].  
Other relevant pathogenic mediators include cytokines such as IL-6 and proliferative factors such as 
PDGF or CTGF that could be targeted with intracellular signalling inhibitors. The success of the 
antioxidant bardoxolone methyl in phase II trials of SSc-associated PAH points towards a possible role 
for cellular stress via mitochondrial dysfunction, oxidant stress and/or inflammation-induced damage in 
PAH pathogenesis. Recent studies implicate circulating adipsin, an adipokine that also regulates 
activation of the alternative complement pathway, in SSc-associated PAH pathogenesis [55], and some 
SSc-specific genetic susceptibility loci for PAH have been described [56] and analyzed [57], although no 
major associations have emerged. Thrombosis, which is an important contributor to CTEPH 
pathogenesis, is also evident in some patients with SSc- associated PAH, but not in patients without PAH 
(as observed using optical coherence tomography at initial time of diagnosis) [58]. Unfortunately, the 
risk to benefit ratio of anticoagulant use in patients with SSc-associated PAH is unfavorable, possibly 
because of the high frequency of gastrointestinal lesions in this population [59]. 
SSc-associated PAH might also share pathogenic mechanisms with other forms of pulmonary 
hypertension. In addition, factors that underlie other forms of pulmonary hypertension may be relevant.  
Thus, hypoxia is a key driver of group III pulmonary hypertension. Likewise, cardiac involvement is 
important for determining the development of pulmonary venous hypertension (PVHT) or group II 
pulmonary hypertension. It has been suggested, based on histological analysis, that SSc-associated PAH 
might often have components of PVOD, which could partially explain why some patients respond poorly 
to vasodilator therapy [60]. However, although PVOD is present in some patients with SSc-associated 
PAH on CT imaging, the overall frequency seems to be relatively low [61]. 
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[H1] Assessment of lung involvement  
Systematic approaches for screening and assessing patients with SSc for lung involvement are associated 
with greater ascertainment of major organ-based complications and improved long-term survival [62] 
compared to historic cohorts without regular screening. Thus, a comprehensive assessment at initial 
diagnosis followed by a regular systematic assessment of cardiorespiratory function is recommended for 
all patients with SSc [63]. This strategy is important for the management of lung disease, for a 
differential diagnosis and to help evaluate the treatment response, which can be challenging owing to 
the multiple mechanisms of disease and comorbidity. The investigation of lung involvement in SSc 
generally starts with a clinical examination and simple imaging such as chest radiography followed by 
formal lung function testing and CT imaging. Lung function tests include measures of lung volume such 
as total lung capacity (TLC) and forced vital capacity (FVC) and measures of gas exchange determined by 
the diffusing capacity for carbon monoxide (DLCO), which can be expressed for the whole lung or 
corrected for the measured alveolar volume (termed the gas transfer coefficient). CT imaging is the best 
way for evaluating lung fibrosis whereas a right heart catheterization is required for a formal diagnosis 
of pulmonary hypertension, even if already suspected on the basis of clinical features or 
echocardiography. 
Exertional dyspnoea is a common presenting symptom in patients with either pulmonary fibrosis or 
pulmonary hypertension. Worsening exertional dyspnoea in patients with SSc is an important symptom 
that should prompt further evaluation for lung complications. However, the differential diagnosis for 
patients with SSc and dyspnoea is broad, reflecting the multiplicity of disease-related mechanisms and 
other confounding factors that contribute to dyspnoea (Box 1). 
Loss of exercise tolerance in patients with SSc is commonly multifactorial.  The cumulative effect of SSc 
and comorbidities on exercise capacity has been quantified using the Frailty index, which reflected the 
severity of dyspnoea [64]. Determining the contribution of cardiopulmonary limitation to exercise 
intolerance is difficult because of two important confounding factors: anxiety and fatigue. In patients 
with anxiety, hyperventilation might cause dyspnoea or heighten dyspnoea severity, especially in well-
informed patients who are sensitized to the dangers of cardiopulmonary involvement in SSc. Fatigue, a 
frequent source of disability in patients with SSc [65], might manifest as exercise intolerance and the 
distinction between limiting fatigue and limiting dyspnoea is often difficult to make. 
In severe pulmonary fibrosis or PAH, prominent exercise intolerance can usually be confidently ascribed 
to lung involvement. However, in the remaining patients presenting with dyspnoea but without 
prominent exercise intolerance a form of exercise testing (the six-minute walk test) enables the 
assessment of cardiopulmonary function (using the point of oxygen desaturation as a measure of 
exercise tolerance), and this may identify other causes such as cardiac dysfunction [66,67].  
[H2] Diagnosis of lung fibrosis 
All patients with SSc should be thoroughly examined for the presence of lung fibrosis at initial 
presentation and during follow up. Regular assessment increases the chance of detecting lung fibrosis 
early, thus enabling an early intervention. Currently, CT imaging is the best tool for detecting lung 
fibrosis and enables the pattern and extent of disease to be determined [68]. In addition, CT imaging 
seems to be more reliable than screening patients using lung function tests.  The normal limits for lung 
function tests range from 80% to 120% of the average value for a person of the same sex, weight and 
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height (as predicted by a computerized lung function test algorithm) and this wide range means that 
many patients with pulmonary fibrosis do not show overt impairment at initial screening [69]. However, 
lung function tests should still be performed at baseline and are the cornerstone of longitudinal follow 
up [52].  
Other methods for assessing patients with SSc are available, such as routine chest radiography, exercise 
tolerance testing and dyspnoea scores, but these methods have limited use for detecting early 
pulmonary fibrosis. Routine chest radiography lacks the sensitivity for detecting pulmonary fibrosis but 
might be performed to assess other pathologies. Measures of exercise tolerance also have a limited 
sensitivity, probably owing to the confounding effects of extrathoracic manifestations of SSc [70], 
although measuring exercise tolerance might be valuable in the exclusion of clinically meaningful 
disease once lung fibrosis has been identified. Likewise, dyspnea scores are of limited use in the 
diagnosis of lung fibrosis but are valuable for trials or the longitudinal follow up of patients [71]. 
Although researchers have developed risk scores for the prediction of lung complications in patients 
with SSc (as discussed in the next section), at present a systematic approach for the screening and follow 
up of patients with SSc is important and justified by the high overall risk of developing severe lung 
fibrosis [52].   
 [H2] Screening and diagnosis of pulmonary hypertension 
The high risk of pulmonary hypertension in SSc, and the major effect that pulmonary hypertension has 
on survival and quality of life [72], justifies the screening of patients. Hence, screening patients with SSc 
for pulmonary hypertension is recommended in clinical practice and a number of screening approaches 
have been developed. Patients should be screened for pulmonary hypertension at least once a year as 
early diagnosis can enable early treatment that could improve the long term outcome.  
One of the first advocated screening approaches, developed as a result of the French itinerAIR study, 
used echocardiographic thresholds to prompt routine right heart catheterization [73]. In the past few 
years, other approaches have been developed that integrate lung function, echocardiography and the 
presence of other relevant markers such as N-terminal pro-brain natriuretic peptide (Nt-proBNP) [74]. 
Results from comparative studies suggest that these screening tools all perform well in clinical practice 
[71,75,76]. For example, one approach is to use the DETECT algorithm, an evidence-based tool that 
integrates non-invasive clinical and laboratory variables and echocardiography, to assess the risk of PAH 
(Figure 2) [77] DETECT was developed in a large cross-sectional cohort [77] to integrate non-invasive 
tests and minimize missed diagnoses of PAH.  When considering lung function tests, it is important to 
consider that concurrent emphysema might reduce the utility of measuring gas exchange (DLCO) in 
patients for screening as it may increase FVC and diminish DLco independent of pulmonary 
hypertension. [78,79]. The DETECT cohort included patients with mild PAH and specific determinants of 
PAH progression have been elucidated using data from this cohort [80] and align with variables such as 
Nt-pro-BNP and low DLco identified in other cohorts [52, 81,82]. The DETECT algorithm first examines six 
variables (FVC, telangiectasia, ACA positivity, electrocardiogram right axis deviation and serum levels of 
Nt-pro-BNP and urate) to generate a score. If this score is above a defined threshold, an echocardiogram 
is recommended and various echocardiograph measures (the tricuspid regurgitant jet velocity and right 
atrial area) are used to generate the final DETECT score. If the DETECT score surpasses a defined 
threshold, a right heart catheterization is recommended as the patient has a significant risk of PAH. The 
DETECT score was devised from data of patients with SSc who had a disease duration of over 3 years and 
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a predicted DLCO of <60% (the DETECT cohort) and so this approach is best suited for use in such 
patients. Otherwise, echocardiography, lung function testing and measurements of Nt proBNP (N-
terminal pro-brain natriuretic peptide), together with clinical assessment, are the main tools for 
assessing the risk of PAH.  
Defining the presence of other connective tissue diseases in patients with SSc-associated pulmonary 
hypertension is important as patients with overlap features might benefit from concurrent 
immunosuppression [83]. All screening programmes can help identify patients with borderline elevation 
of mean pulmonary arterial pressure (mPAP), which is associated with distinct characteristics [84] and a 
high risk of developing PAH during follow up and so such patients need to be carefully monitored 
[85,86]. Defining the presence of increased pulmonary artery wedge pressure (PAWP) in SSc-associated 
PAH is also important as this feature can affect the disease outcome and reduce response to PAH 
specific therapy [87]. Mixed phenotypes with elements of lung disease and possible post-capillary 
components probably also occur and need careful evaluation and treatment to ensure that treatable 
precapillary components are defined and addressed [88]. In a 2017 study, patients with SSc-associated 
PAH who had a preserved pulmonary vascular bed (as assessed using optical coherence tomography 
(OCT) at right heart catheterization to directly image the intrapulmonary vessel wall thickness and 
structure) showed a better response to PAH specific treatment than those patients with a damaged 
pulmonary circulation [58]. This finding is in line with other outcome studies suggesting that milder 
disease is associated with better outcomes than severe disease and fits with the current 2015 ERS/ESC 
recommendations for risk assessment and treatment [89].   
Exercise testing could be an additional useful screening test for pulmonary hypertension but other 
musculoskeletal and extrathoracic manifestations might confound results [90,91]. More comprehensive 
risk prediction scores for pulmonary hypertension are in development but the value of these scores are 
presently limited and require validation. Identifying patients who have a very low risk of developing 
PAH, and hence who do not require intensive screening, can be more important than identifying those 
at high risk. MRI is emerging as a non-invasive tool that might help stratify patients [92] and diagnose 
the presence of pulmonary hypertension but is not yet used in routine assessment of PAH-associated 
SSc. Autoantibodies, especially anti-U3 RNP, ACA, anti-RNA polymerase III and anti-Th/To RNP 
antibodies, are helpful in defining increased or reduced risk of PAH and are helpful in risk stratification 
[93]. The extent and severity of concurrent lung fibrosis is important as it might suggest a diagnosis of 
group III pulmonary hypertension and needs to be carefully defined [94]. 
[H1] Classification of lung involvement  
[H2] Classification of interstitial lung disease  
The classification of interstitial lung disease is complex but historically this disease has been sub-
classified on the basis of histological patterns observed in lung biopsy samples (Figure 3). The most 
common histological subtype that occurs in patients with SSc is non-specific interstitial pneumonia 
(NSIP) [67]. Although a sub-classification of NSIP was originally based upon histological patterns, 
correlations between lung biopsy and CT findings mean that patients with NSIP can be identified with 
high confidence using CT imaging [68]. NSIP can be further subdivided into reversible cellular NSIP and 
irreversible fibrotic NSIP subtypes based on the degree of inflammation present in the lung [95]. A 
minority of patients with SSc have another histological pattern referred to as usual interstitial 
pneumonia (UIP), which is the defining histological pattern of idiopathic pulmonary fibrosis. In idiopathic 
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lung fibrosis the UIP pattern is associated with a much faster progression and worse survival than NSIP, 
however, the major prognostic distinction observed between NSIP and UIP patterns of disease 
(histologically or by CT imaging) in idiopathic pulmonary fibrosis does not apply to SSc-associated ILD. 
The outcome of SSc-associated ILD is much better than idiopathic pulmonary fibrosis [96] and the 
mortality is similar for patients with SSc-associated ILD and a NSIP pattern and those patients with a UIP 
pattern [95,96].  
Some patients with SSc can also have other forms of interstitial lung disease.   For example, 
fibroelastosis is increasingly being recognized as a feature of connective tissue disease-associated ILD 
and can occur in association with pleural abnormalities and resembles idiopathics pleuroparenchymal 
fibroelastosis (a rare form of ILD with a poor prognosis). This form of ILD might be more progressive 
than other forms of SSc-associated ILD [97]. Currently, the precise frequency and clinical relevance of 
fibroelastosis in SSc-associated ILD is unknown [98]. Patients with overlap SSc, which represents up to 
20% of patients with SSc [99], exhibit clinical features of the overlapping disease (for example, myositis 
or systemic lupus erythematosus (SLE)), which can include parenchymal lung disease. For example, 
myositis is associated with organizing pneumonia and SLE is associated with shrinking lung syndrome or 
lymphocytic interstitial pneumonias (LIP) [67].  
Analyses of patient cohorts in the past few years has provided further insights into the timing and 
frequency of clinically important lung fibrosis development in SSc. Up to half of patients with dcSSc 
eventually develop severe lung fibrosis and many of these patients develop this complication within the 
first 3 years following diagnosis and can have considerable lung involvement at initial presentation 
[52,100]. This finding has important implications for treatment strategies aiming to prevent or attenuate 
worsening of disease. Overall, the frequency of lung fibrosis in patients with lcSSc is approximately half 
that of dcSSc (meaning approximately one quarter of patients with lcSSc are affected). Lung fibrosis is 
associated with different patterns of antinuclear antibodies (ANA), in particular anti-topoisomerase-1 
antibodies. Approximately two thirds of patients that are positive for the anti-topoisomerase-1 
ultimately develop moderate to severe ILD [5]. Other less common antinuclear antibodies (ANA) such as 
anti-U11/U12 ribonucleoprotein (RNP) antibodies or anti-Th/To RNP antibodies are also associated with 
lung fibrosis [101]. Interestingly, the presence of anti-centromere antibodies (ACA) or anti-RNA 
polymerase III antibodies (ARA) seems to be negatively associated with severe lung fibrosis [100,101] 
and so presence of these can be used to identify cases at lower risk in clinical practice and encourage 
further investigation of respiratory symptoms.  
[H2] Stratification by lung fibrosis severity  
In clinical practice the most important aspect for managing lung fibrosis in patients with SSc is 
identifying those patients with severe disease or at risk of disease progression. By studying the factors 
associated with disease progression in well characterized cohorts, researchers have defined several key 
risk factors for developing severe lung fibrosis [52], which can be used in clinical practice (Box 2) The 
most important of these factors is the extent of disease severity, particularly in patients in the early 
stages of SSc.  
The importance of determining lung fibrosis severity has led to the development of a simple staging 
system that incorporates CT assessment and measures of FVC. In practice, with this staging system 
patients are first stratified into whether they have clearly mild or extensive fibrosis (<20% lung 
involvement or >20% lung involvement, respectively, by high-resolution CT).  In patients for whom the 
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extent of fibrosis is indeterminable by CT imaging, they are instead stratified into these groups on the 
basis of FVC measurements (>70% for mild fibrosis and <70% for extensive fibrosis) [102]. A designation 
of mild or extensive fibrosis by this staging system is associated with symptoms of dyspnoea and 
impaired exercise capacity [103]. This staging system can also reportedly predict an increased risk of 
considerable future decline; for example, >20% lung involvement is associated with an increased risk of 
decline (as assessed by lung function tests) and decreased survival [104]. Other staging systems have 
also been suggested that are based on the analysis of large SSc cohorts [52] or clinical trial datasets 
[105,106] and include features (such as arthritis) that might reflect clinical subtypes of SSc at high risk of 
developing fibrosis [107]. Other factors that potentially predict future decline include markers of 
epithelial damage, such as serum mucin-1 and DTPA clearance, and circulating markers, such as CXCL4 
and IL-6, although IL-6 is only predictive for patients with mild lung fibrosis [17,108]. At present, all of 
these measures are only useful in research settings pending further validation and standardization. In 
the future, composite markers that incorporate clinical and laboratory measures will probably be 
developed.   
New approaches that use computer assisted quantitation of lung fibrosis are being developed [109,110] 
and might offer further insights into disease progression and the refinement of staging systems in the 
future. As outlined above, baseline tests including CT imaging, lung function tests, ANA testing and the 
assessment of clinical features facilitate the stratification of individuals at high risk of developing severe 
lung disease for whom treatment is a high priority. Such approaches are especially useful in planning 
treatments such as haematopoietic stem cell transplantation (HSCT), which is associated with a high risk 
of treatment-related mortality but also long-term benefits such as increased survival [111]. New data 
suggest that in patients with extensive lung fibrosis (as designated by the severity staging system) [112], 
serial lung function testing can be used to monitor disease progression and predict mortality; for 
example, a drop of >10% FVC at 12 months is the strongest single predictor of mortality). Additionally, a 
5-9% decline in FVC alongside a 15% fall in DLCO at 12 months is also predictive of disease mortality. 
These thresholds might be useful in the evaluation of treatment responses, making treatment decisions 
and identifying patients for inclusion (or exclusion) in clinical trials [109]. Change in lung function, 
assessed by fall in FVC, is an important component of the newly developed composite response index 
for SSc clinical trials [113], and a decrease in lung function is associated with worse outcomes [114]. 
Finally, as discussed above, particular ANAs are also associated with an increased or decreased risk of 
lung fibrosis [100,101].  
 [H2] Classification of pulmonary hypertension 
The classification of pulmonary hypertension in SSc follows that of pulmonary hypertension associated 
with other diseases and it is important to consider the multiple way in which pulmonary hypertension 
can develop. Pulmonary hypertension is conventionally divided into five groups on the basis of clinical 
and pathobiological features (Table 1). Overall, PAH (classified by the WHO as group I) is probably the 
most frequent form of pulmonary hypertension, but mixed forms (such as pulmonary hypertension with 
lung fibrosis and cardiac involvement) also exist. More than half of patients with SSc-associated 
pulmonary hypertension have PAH, but a considerable number of patients have post capillary 
pulmonary hypertension (WHO Group II) or pulmonary hypertension associated with lung fibrosis or 
hypoxia (WHO Group III) [52]. Pulmonary hypertension associated with lung fibrosis is generally defined 
as lung fibrosis affecting >20% of the lung volume, although precise estimates of the extent of lung 
fibrosis can be challenging in routine clinical practice [115] and fibrosis can be exacerbated by the co-
11 
 
existent of emphysema [116]. In addition, some patients have concurrent pulmonary veno-occlusive 
disease (PVOD, WHO Group 1’) or chronic thromboembolic pulmonary hypertension (CTEPH, WHO 
Group IV). The incidence rate of pulmonary hypertension of any form is approximately 1-2% per year in 
patients with SSc [52]. However, the frequency of pulmonary hypertension varies across different 
reports depending upon the duration of follow up; the frequency might be 5% for a cohort with an 
average disease duration of 5 years, 10% for a disease duration of 10 years and 15% for a disease 
duration of 15 years [52]. This increase in frequency differs from other complications of SSc, such as 
renal crisis, that generally occurs in early disease and is consistent with SSc representing a susceptibility 
phenotype for the development of pulmonary hypertension.  
[H1] Treatment approaches  
[H2] Treatment approaches for lung fibrosis 
Immunosuppression remains the cornerstone for treatment of SSc-associated lung fibrosis. The benefits 
of immunosuppression are largely supported by findings from observation studies and retrospective 
studies [116,117]. However, limitations of the open label and retrospective design of most studies 
underpins the need for prospective randomized studies. A limited number of prospective clinical trials 
have been performed and show immunosuppression has beneficial effects. The most notable of these 
studies is the Scleroderma Lung Study I (SLS I) that compared oral cyclophosphamide over 12 months 
with placebo [118]. In this study, oral cyclophosphamide was efficacious but only had a marginal 
treatment benefit and substantial toxicity. However, the fact that the benefit observed was only small 
reflected the inclusion of many patients with mild non-progressive lung disease whereas post hoc sub-
analyses suggested that in extensive disease, cyclophosphamide therapy had major benefits in 
preventing disease progression, based on lung function testing. The results of a 2-year follow-up study 
suggested that the benefit of oral cyclophosphamide might continue to 18 months (the placebo 
subtracted difference at 18 months was 7%) but was possibly attenuated by 24 months [119].  
The Fibrosing Alveolitis in Scleroderma Trial (FAST) trial had a similar design to the SLS I trial but 
investigated 6 months of intravenous cyclophosphamide followed by oral azathioprine. After 12 months, 
the benefits of this treatment were no different from placebo, although FVC showed a trend towards 
improvement in the treatment group compared with the placebo group that did not reach statistical 
significance [120]. In the Scleroderma Lung Study II (SLS II), mycophenolate mofetil (MMF) was as 
efficacious as oral cyclophosphamide in improving cough-specific measurements [121], which was also 
observed when the data from both SLS studies were combined, to include the placebo control from SLS I 
[122] However, the tolerability of MMF was superior to cyclophosphamide and MMF is now used as a 
first line treatment in most centers [123]. The optimal dose of MMF for the treatment of SSc-associated 
ILD is probably 3g/day, which was the target dose in the SLS II trial, although for patients who struggle to 
tolerate 3/g day, 2g/day might be considered. Further support for immunosuppression in SSc lung 
fibrosis comes from the American Scleroderma Stem Cell versus Immunosuppression Trial (ASSIST) 
[124], the Autologous Stem cell Transplantation International Scleroderma ASTIS [111] trial and, in 2018, 
the Scleroderma: Cyclophosphamide or Transplantation (SCOT) study [125], which all compared 
intravenous cyclophosphamide with HSCT. In all three studies, HSCT was superior to cyclophosphamide 
therapy alone. However, the transplant-related mortality with HSCT was lower in the SCOT study than in 
the larger ASTIS trial. The SCOT study had a focus on lung fibrosis outcomes and in this study there was 
some impressive apparent improvement in established lung fibrosis, based upon computer assisted 
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quantitative CT analysis, that point towards potential reversibility of lung fibrosis. However, HSCT 
remains a major undertaking and potential transplant-related mortality means that patients should be 
carefully selected for therapy, which emphasizes the value of staging or stratifying patients with SSc so 
that this therapy can be considered at a time when it might be best tolerated.  
Although the SCOT study highlights the potential benefit of HSCT in treating SSc lung fibrosis, a similarly 
beneficial but less toxic treatment is necessary. Such a need is providing impetus for clinical trials that 
test biological strategies or the use of new agents in combination with immunosuppression such as 
MMF or B cell depletion with rituximab [126]. lung fibrosis such as IL-6R blockade can alter markers of 
fibrogenic macrophage differentiation or fibroblast activation [127] and tocilizumab (an IL-6 inhibitor) is 
being further tested in ongoing clinical trials of SSc [128]. The role of the adaptive immune compartment 
in SSc lung fibrosis development is supported by studies of lymphocytes isolated from bronchoalveolar 
lavage fluid [10] that show markers of T cell activation [10] and the association of lung fibrosis with 
specific antibody reactivities [5, 129]. Thus, both T cell and B cell lineages might be relevant in lung 
fibrogenesis, which could explain the apparent benefit of immunosuppressive therapies in some 
patients [130]. For example, B cell depletion is effective in the treatment of some patients who are 
refractory to other therapies, providing strong support for the contribution of B cells to the pathogenic 
micro-environment in SSc-associated lung fibrosis [131].  
Emerging clinical trials undertaken to test novel therapies include blockade of TGF [132] and its 
activation by epithelial alpha integrin [133] [https://clinicaltrials.gov/ct2/show/NCT02745145], the IL-
13–IL-4 axis and IL-4 [134]. In addition, two anti-fibrotic agents that can retard disease progression in 
idiopathic pulmonary fibrosis are currently undergoing evaluation in SSc-associated ILD: pirfenidone and 
nintedanib. Pirfenidone has already been evaluated in a small phase II study (LOTUSS) [135] and the SLS 
III trial comparing MMF combined with pirfenidone treatment and MMF treatment alone is ongoing 
[136] [https://clinicaltrials.gov/ct2/show/NCT03221257] A large phase III trial investigating the safety 
and efficacy of nintedanib in SSc-associated lung fibrosis is ongoing [137,138, 
https://clinicaltrials.gov/ct2/show/NCT02597933]. However, trials of lung fibrosis in SSc are challenging 
and some studies have failed to recruit enough patients [139] or have had unequivocally negative results 
[140,141].  
In addition to immunosuppression for patients with extensive fibrosis or those predicted to be at risk of 
lung disease progression, other general measures for the treatment of SSc-associated lung fibrosis 
include vigorous management of gastro-oesophageal reflux [142]. Combinations of antacids (acid 
suppressive agents) and prokinetics, as well as simple lifestyle measures, are used in the treatment of 
gastro-oesophageal reflux. Oxygen therapy can also be useful for reducing exertional dyspnoea and 
patients with severe lung disease might benefit from long term low dose oxygen therapy to reduce the 
risk of developing secondary pulmonary hypertension (WHO Group III). Oxygen therapy should be 
administered following general respiratory practice guidelines. Another important treatment approach 
in SSc-associated lung fibrosis is the management of infection. Prophylactic antibiotics should be 
considered for preventing community acquired infection in patients reporting frequent lower 
respiratory tract infections, and for preventing opportunistic infections such as pneumocystis in patients 
receiving long-term intensive immunosuppression [142].  
 [H2] Treatment approaches for PAH  
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PAH management has made substantial advances over the past 2 decades, especially regarding oral 
therapies and the growing evidence base for the use of drug combinations [143]. Therapies have 
progressed from a time when only intravenous epoprostenol was available [144,145] and outcomes 
were very poor, to the current availability of multiple licensed treatments that can be used in 
combination (Table 2). The early studies that led to the licensing of various PAH therapies, including 
bosentan and sildenafil, focused on short term gains in exercise capacity; in these studies, the response 
of patients with SSc-associated PAH or CTD-associated PAH was often less efficacious than patients with 
other forms of PAH, although most treatments seem to result in meaningful benefit in the majority of 
patients with SSc-associated PAH [146,147,148,149]. However, evidence in clinical practice suggests that 
these therapies have long-term benefits in SSc-associated PAH [142],  which is supported by key event-
driven clinical trials published in the past 3 years  [150,151,152]: the SERAPHIN trial (which tested the 
oral endothelin receptor antagonist macitentan), the GRIPHON trial (which tested the prostcyclin-
receptor agonist selexipag) and the AMBITION trial (which tested a combination therapy of ambrisentan 
(endothelin receptor antagonist) and tadalafil (a PDE5 inhibitor)). 
Treatment strategies have defined key potential pathogenic and protective mechanisms in PAH. For 
example, endothelin (ET1), a potent vasoconstrictor and pro-proliferative peptide, is a probable 
pathogenic factor [147, 148]. Whereas the nitric oxide pathway (which mediates vasodilation through 
soluble guanylate cyclase) is probably a protective factor as soluble guanylate cyclase stimulators and 
inhibitors of phosphodiesterase 5 (an enzyme that breaks down guanylate cyclase) have shown some 
promise in the treatment of SSc-associated PAH [143]. Similarly, prostacyclin-dependent pathways are 
protective and defects in these pathways might be important in pathogenesis [144]. The effectiveness of 
combination therapies, such as ambrisentan and tadalafil suggests that multiple pathways and 
mediators are likely involved in the development of PAH in SSc [153] 
All the pivotal trials of new PAH treatments over the past few years have included considerable numbers 
of patients with CTD-associated PAH or SSc-associated PAH, which has enabled subgroup analyses and 
helped to establish licensed drugs for PAH in SSc (Table 3). The findings of these trials generally support 
the efficacy of specific licensed PAH treatments in PAH-associated SSc and are in line with emerging 
registry and retrospective cohort data [59]. The results of the three large, long-term event-driven trials 
were positive and suggest that these treatments are efficacious in patients with CTD-associated PAH, 
which is in line with the efficacy observed in the overall cohort that included patients with idiopathic or 
heritable PAH [150,151,152,154,155]. Studies of riociguat (a soluble guanylate cyclase stimulator) have 
shown similarly encouraging results in terms of long-term survival [156]; although the phase III trial 
examined exercise capacity as a primary end point and and showed less benefit in PAH-CTD, the earlier 
studies examined the six-minute walk test distance for which the response of patients with CTD-
associated PAH or SSc-associated PAH was less overall than of patients with idiopathic PAH or the 
overall cohort [156]. Evidence-based recommendations are available for the treatment of pulmonary 
hypertension [89] and SSc-associated PAH [63]. Current recommendations support an aggressive use of 
combination treatments in patients with SSc at high risk of PAH [89], which is now recommended by 
most expert centers. Patients with mild PAH or those patients with mixed PH phenotypes might require 
a less aggressive treatment.  Emerging evidence from cohort studies support the beneficial effects of 
intensive combination therapy (including a substantial improvement in survival) in the most severe 
cases of SSc-associated PAH [157]. 
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The presence of cardiac disease or lung fibrosis is important to consider in SSc-associated PAH as these 
pathologies might occur concurrently, potentially resulting in a phenotype with a mixed aetiology that 
can affect the outcome and treatment response. For example, pulmonary vasodilators might be 
disadvantageous if they worsen the ventilation–perfusion ratio in pulmonary hypertension associated 
with lung fibrosis and detrimental in patients with a degree of post-capillary pulmonary hypertension 
owing to cardiac involvement. However, data from the GRIPHON study and other emerging data suggest 
that some patients with a degree of group II pulmonary hypertension in associated with PAH might 
benefit from specific PAH. The occurrence of PVOD and the risks associated with PVOD are also 
important to consider. PVOD occurring in SSc might be a mixed phenotype rather than a pure form of 
PVOD and could possibly respond to careful use of vasodilators [61]. Patients with complex forms of 
pulmonary hypertension should be managed by experts in SSc and experts in pulmonary hypertension 
collaboratively in specialist units to ensure that affected patients receive optimal treatment. 
 [H2] Role of lung transplantation  
Lung transplantation is a potential treatment option for some patients with SSc who have pulmonary 
hypertension or lung fibrosis. However, choosing whether to use this treatment is difficult as lung 
transplantation is associated with a high frequency of relevant comorbidity including gastroesophageal 
reflux disease [158,159]. Challenges related to previous treatment, steroid use and gastro-oesophageal 
reflux are important as they may impact on post-transplant complications and outcome. [160]. 
However, case series from the past decade suggest that transplantation has favourable outcomes in 
many patients with SSc and long-term survival is comparable to that observed in patients with other 
multisystem diseases; hence, for some patients with SSc, heart, lung or combined transplantation is an 
important therapeutic option [161,162]. 
 
[H1] Conclusions 
In this review, we highlight the ongoing challenges of lung complications in SSc but also provide clear 
evidence of the changing landscape in terms of understanding pathogenic mechanisms, assessing 
patients and providing treatments that effect outcomes [163]. The timing and frequency of lung fibrosis 
and pulmonary hypertension in SSc indicates that both complications are important and relatively 
frequent. An increasing understanding of pathogenetic pathways means that the expanding number of 
targeted biological or synthetic agents that target specific pathway or mediators can be tested and a 
better understanding of clinical trial design for lung fibrosis and PAH will ensure that the data obtained 
are robust and reliable. The situation is considerably more positive than a decade ago and tangible 
progress will probably be made over the next few years. The ultimate test will be increasing long term 
survival with better quality of life for patients with SSc, as observed after autologous stem cell 
transplantation [125].  
Thus, despite the challenges of SSc there is reason to be optimistic because an unprecedented number 
of drugs are being tested in clinical trials for targeting lung and skin involvement in SSc, including 
treatments that might target fibrosis in both sites. Moreover, as the cost of PAH therapies becomes 
lower as generic formulations become available, opportunities arise to implement combination 
treatment at an early stage of disease. Identification of patients with a poor prognosis at an early stage 
of disease will enable better targeting of treatment and might start to diminish the high mortality seen 
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in some patients with SSc [164,165]. High-quality recommendations and guidelines are now available 
[63,166] that provide a roadmap for best practice and will undoubtedly be further updated as new 
evidence-based treatments for lung disease emerge. The future is bright as better tools for screening 
and diagnosis are being developed and a greater understanding of fundamental pathogenic mechanisms 
and identification of new potential therapeutic targets is being unveiled. Treatments for established 
lung complications are now available and various others are in clinical trials so that treatment 
approaches that prevent the progression of fibrosis and pulmonary hypertension will likely soon emerge 
as well as better ways to predict those at risk of major lung complications.  
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 Lung complications are frequent in systemic sclerosis (SSc) and include lung fibrosis and 
pulmonary hypertension which have a substantial impact on disease outcomeand are both 
major causes of SSc-related death. 
 Systematic valuation of patienst ensures that diagnosis of lung fibrosis and pulmonary 
hypertension is timely and permits treatment at earliest possible stage. 
 There are multiple licensed therapies for pulmonary arterial hypertension and use of these 
agents alone and in combination has improved outcome and survival in event driven morbidity-
mortality trials. 
 There are no approved therapies for lung fibrosis but treatment with immunosuppression 
appears beneficial in recent clinical trails and is recommended for appropriate cases with severe 
or progressive lung fibrosis. 
 
 
Box 1: Potential causes of dyspnoea in patients with systemic sclerosis 
Parenchymal lung disease 
- In addition to typical systemic sclerosis (SSc)-associated interstitial lung disease (ILD), some 
patients with overlap syndromes might present with patterns of lung involvement associated 
with other autoimmune rheumatic diseases [67], such as organizing pneumonia (a frequent 
feature in myositis [and airway involvement (seen in rheumatoid arthritis and Sjögren 
syndrome) [67].  
Respiratory comorbidities 
- Comorbidities including smoking-related emphysema, infection and pulmonary 
thromboembolism can cause dyspnoea. 
 
Pulmonary vasculopathy 
- Pulmonary arterial hypertension (PAH) can present with exertional dyspnoea. In some patients, 
pulmonary vascular disease is not sufficiently severe to manifest as PAH at rest but can cause 
exertional dyspnoea owing to a loss of pulmonary vascular reserve [71]. [  
 
Cardiac involvement 
- Dyspnoea might be caused by systolic or more commonly diastolic dysfunction, rate or rhythm 
disturbances [5] or from pericardial effusion. Cardiac involvement is frequent in SSc but can be 
challenging to diagnose and is not always symptomatic [66].   
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Cardiac comorbidities 
- Coronary heart disease and valvular heart disease (especially aortic stenosis) can cause 
dyspnoea and might be associated with angina, but dyspnoea without concurrent angina may 
reflect otherwise unsuspected cardiac comorbidity in some patients. 
 
Anaemia 
- This condition might arise from a variety of mechanisms and cause dyspnoea and might also 
aggravate other manifestation such as PAH [5]. 
 
Arthritis 
- Arthropathy, owing to either autoimmune disease or concurrent osteoarthritis, can, in isolation, 
cause exertional dyspnoea because of the increased work of locomotion 
 
Muscle involvement 
- Peripheral muscle limitation because of autoimmune muscle involvement is an often-
underestimated contributor to exercise limitation [167] 
 
Conditioning 
- Cardiorespiratory and musculoskeletal conditioning is a common cause of subjective exertional 
dyspnoea in SSc [5], which might be amplified if loss of fitness is associated with significant 
weight gain. 
 
 
 
Box 2 Risk factors for severe lung fibrosis in systemic sclerosis [Au: Only one of these risk factors has 
a reference cited. Could you provide references for the other risk factors listed here?] 
 Diffuse cutaneous systemic sclerosis [50] 
 Less than 3 years disease duration [50] 
 Severe gastro-oesophageal reflux [22, 23] 
 The presence of antinuclear antibodies (in particular anti-topoisomerase-1 antinuclear 
antibodies, but also anti-Th/To ribonucleoprotein (RNP) antibodies or anti-U11/U12 RNP 
antibodies) [94] 
 A ‘severe’ score by the UK-RSA Staging system [96] 
 Declining lung function [50] 
 Evidence of epithelial damage (for example, elevated KL-6 or fast DTPA clearance) [25] 
  
  
Table 1  Classification of pulmonary hypertension in systemic sclerosis 
WHO 
Group 
Designation for 
management 
Investigation and diagnosis Approximate frequency in SSc Treatment considerations Features  
I Precapillary 
pulmonary arterial 
hypertension (PAH) 
PAH is defined by mPAP ≥ 
25 mm Hg with PAWP ≤ 15 
mm Hg and PVR ≥ 3 WU 
without major lung fibrosis 
PAH is the most common cause of 
severe  pulmonary hypertension in 
SSc and probably accounts for 
~60% of patients with SSc-
associated pulmonary hypertension 
[77]  
Supportive measures and targeted PAH 
specific medication can be given, often 
in combination 
Borderline elevation of mPAP (21-14 
mm Hg) is associated with high risk of 
developing established PAH [82] 
I’ Pulmonary veno-
occlusive disease 
(PVOD) 
PVOD has a similar 
haemodynamics to PAH but 
presents with CT findings of 
septal lines, nodules and 
lymphadenopathy 
The frequency of PVOD in SSc is 
unknown but up to 15% of patients 
with SSc-associated pulmonary 
hypertension might have elements 
of PVOD [61]. PVOD is rarely 
observed as the pure cause of 
pulmonary hypertension  
Supportive measures and vasodilator 
therapy can be used but the latter 
should be used with care as this 
therapy might otherwise precipitate 
pulmonary oedema  
Immunosuppressive therapy might be 
beneficial for some patients.  
The frequency of apparent PVOD 
varies between cohort studies and 
some patients might have both PVOD 
and Group I PAH [60,61]. 
II Post-capillary 
pulmonary 
hypertension 
Group II pulmonary 
hypertension is 
characterized by elevated 
PAWP above 15 mm Hg in 
association with pulmonary 
hypertension mPAP > 25 
mm Hg 
In ~15% of patients with SSc-
associated pulmonary 
hypertension, group II pulmonary 
hypertension is the major form [77] 
However, the frequency of group II 
pulmonary hypertension is difficult 
to determine. In the context of 
scleroderma renal crisis with 
systemic hypertension, this form is 
the most likely explanation for 
concurrent pulmonary 
hypertension and might later 
improve without specific therapy.  
The cardiac cause (including systolic or 
diastolic failure, arrhythmia and 
valvular disease) should be treated. In 
some patients, vasodilator therapy 
with PAH specific therapies might be 
considered but these therapies might 
worsen heart failure and so need to be 
used with some caution. 
The true frequency of this form of 
hypertension is unclear, and some 
studies suggest that there is often a 
post-capillary component to 
pulmonary hypertension in SSc, 
which might be apparent with a fluid 
challenge at right heart 
catheterisation. This form might 
sometimes co-exist with Group I PAH 
[66] 
III Pulmonary 
hypertension owing 
to lung fibrosis or 
hypoxia  
In SSc, this form of 
pulmonary hypertension is 
difficult to classify as many 
patients have some degree 
of lung fibrosis. A diagnosis 
of pulmonary hypertension 
Approximately 15% of patients with 
SSc-associated pulmonary 
hypertension are estimated to have 
Group III pulmonary hypertension  
Treatment of any associated chest wall 
skin fibrosis, myositis and lung fibrosis 
should be prioritized. Subsequently, 
judicious use of vasodilator therapy 
might be considered, but should be 
used with caution as this therapy might 
Lung fibrosis occurs in over 50% of 
patients of SSc and so fibrosis often 
co-exists with other forms of 
pulmonary hypertension. Therefore, 
simply demonstrating the presence 
of any lung fibrosis is not usually 
  
associated with lung 
fibrosis is normally made if 
specified thresholds of 
various tests of lung 
function are exceeded: for 
example, >70% predicted 
FVC (by spirometry) or 
>20% fibrotic lung volume 
involvement (by HRCT) .  
aggravate hypoxia owing to a 
decreased ventilation to perfusion 
ratio  
sufficient for classifying patients into 
this group [52]. 
IV Thrombo-embolic 
pulmonary 
hypertension 
All patients with suspected 
PAH should be investigated 
to exclude chronic 
thromboembolic disease as 
this form of pulmonary 
hypertension can be 
treated surgically.  
Research studies suggest that intra 
vascular thrombosis is present in 
some cases of SSc-associated PAH 
but others develop more typical 
CTEPH [58].   
The management of thrombo-embolic 
disease should be in line with current 
recommendations and includes surgical 
treatment, medical therapy and, when 
suitable, balloon pulmonary 
angioplasty. Routine use of 
anticoagulants in PAH in SSc is not 
associated with better outcome and so 
is not recommended. 
This is uncommon as a major cause 
of pulmonary hypertension in SSc but 
mural thrombosis (a thrombosis that 
partially blocks the blood vessel) 
might be observed in vessels by 
imaging [58]. 
V Uncommon and 
multifactorial 
pulmonary 
hypertension 
Routine pulmonary 
hypertension investigation 
supplemented with 
extensive additional tests 
should be used to confirm 
multifactorial and/or 
uncommon causes  
Rare causes of pulmonary 
hypertension might co-exist with 
SSc. In addition, individuals with 
pulmonary hypertension arising 
from multiple mechanisms might 
be considered as part of this group 
Type V pulmonary hypertension is a 
heterogeneous group that includes 
forms with various mechanisms and 
pathologies and so the frequency will 
depend on what definition of 
mechanisms thatare included in this 
group. 
Patients might have pulmonary 
hypertension with multifactorial 
elements but usually one of these 
factors predominates  
FVC, forced vital capacity; HRCT, high-resolution CT; mPAP, mean resting pulmonary arterial pressure; PAWP, pulmonary arterial wedge 
pressure; PVR, pulmonary vascular resistance; SSc, systemic sclerosis 
  
  
Table 2  Summary of therapies approved for use in SSc-associated PAH  
 
Drug 
 
Delivery route Evidence for efficacy in SSc-associated PAH [Au: For this 
column, could you please clarify on the findings of 
the studies presenting this evidence, and provide 
references] 
Major adverse effects Comments  
Endothelin receptor antagonists 
Bosentan 
 
Oral Similar treatment effect seen in SSc subgroup to the 
overall treatment cohort in pivotal trials  
Abnormal liver function tests, 
anaemia, oedema and nasal 
congestion 
The first oral therapy licensed 
for SSc-associated PAH. 
Anecdotal improvement in long 
term outcome and preventing 
mortality [149] 
Ambrisentan 
 
Oral Similar treatment effect seen in SSc subgroup to the 
overall treatment cohort in pivotal trials and ambrisentan 
in combination with tadalafil is highly efficacious  
Anaemia, oedema, fluid 
retention and nasal congestion 
Fewer drug interactions than 
other endothelin receptor 
antagonists [146] 
Macitentan 
 
Oral Demonstrated high efficacy compared with placebo in a 
robust outcome study using morbidity-mortality 
endpoint.   
Anaemia and nasal congestion.  Macitentan in combination with 
a PDE5 inhibitor is also highly 
efficacious [150] 
Prostacyclin pathway targeting therapies  
Beraprost* 
 
Oral No robust efficacy data available Jaw pain, diarrhoea, 
hypotension and headache 
Not licensed in Europe or North 
America.  
Selexipag* 
 
Oral Robust long-term data from Griphon trial including cases 
on triple therapy with an endothelin receptor antagonist 
and PDE5 inhibitor.  There was benefit in morbidity-
mortality for cases treated with selexipag compared with 
placebo, even in cases already on dual combination 
therapy [151]. 
Jaw pain, diarrhoea, 
hypotension and headache 
Also licensed for CTEPH. Cannot 
be combined with a PDE5 
inhibitor [151] 
  
Epoprostenol** Intravenous Demonstrated efficacy in a randomized open label study 
but no mortality benefit reported  
Line sepsis, jaw pain, diarrhoea, 
hypotension, headache and 
rapid worsening if infusion 
interrupted 
Epoprostenol is generally used 
in patients with severe 
pulmonary hypertension, 
particularly patients with class 
IV pulmonary hypertension  [] 
Iloprost** 
 
Inhaled Similar treatment effect seen in SSc subgroup to the 
overall treatment cohort in pivotal trials [167].   
Jaw pain, diarrhoea, 
hypotension and headache 
Inhaled route not popular with 
many patients but other 
formulations not approved 
[169] 
Treprostinil** 
 
Subcutaneous 
or intravenous 
Similar treatment effect seen in SSc subgroup to the 
overall treatment cohort in pivotal trials [OLD 163].   
Injection site pain (from 
subcutaneous administration), 
jaw pain, diarrhoea, 
hypotension and headache  
Pain at site of injection is a 
major limitation [171] 
PDE5 inhibitors 
Sildenafil 
 
Oral Improved exercise capacity for SSc as in overall treatment 
groups in pivotal trial [148] 
Hypotension, interaction with 
nitrates, visual disturbance, 
epistaxis, headache and 
priapism 
Sildenafil is a widely use first 
line therapy and the generic 
formulation is relatively 
inexpensive. This therapy is 
often used in combination with 
an endothelin receptor 
antagonist [148] 
Tadalafil 
 
Oral Improved exercise capacity for SSc similar to overall 
treatment groups in pivotal trial [154] 
Hypotension, interaction with 
nitrates, visual disturbance, 
epistaxis, headache and 
priapism 
Evidence base from studies 
including in combination, most 
robustly from the Ambition 
clinical trial [153]  
Soluble guanylate cyclase agonist 
Riociguat 
 
Oral Data for SSc are in line with overall treatment groups in 
pivotal trial showing benefit of active treatment 
compared with placebo [156] 
Hypotension, epistaxis, 
headache and haemoptysis 
This therapy has the theoretical 
advantage of not depending 
upon endothelial production of 
nitric oxide for efficacy (unlike 
  
other approved therapies)  
[156] 
Prostacyclin pathway targeting therapies include prostacyclin agonists* and synthetic prostacyclins**. 
CTED, chronic thromboembolic disease; PDE5, phosphodiesterase type 5 inhibitor 
  
  
 
Table 3  Clinical trials of therapies in PAH that have included patients with SSc 
 
Treatment (trial 
name) 
Primary 
endpoint 
Total 
number of 
patients 
enrolled 
Number of 
patients with 
CTD-
associated 
PAH (%) 
Patients with SSc-
associated PAH (%)  
Summary of resuts relevant to SSc 
associated PAH 
Reference 
Endothelin receptor antagonists 
Bosentan 
(BREATHE-1 and 
study 351) 
SMWT  245 66 (27%)  
 
52 (79%) These two pivotal trials in PAH led 
to approval of bosentan and 
included cases with SSc associated 
PAH that had qualitatively similar 
treatment benefit to overall cohort 
149 
Sitaxentan 
(STRIDE-1 and 
STRIDE-2) 
 
SMWT  425 110 (26%) 
 
63 (57%) These two trials confirmed 
increase in SMWT in PAH cases 
treated with sitaxentan including 
those with SSc.  Sitaxentan later 
withdrawn due to hepatotoxicity 
168 
Ambrisentan 
(ARIES-1 and 
ARIES-2) 
 
SMWT  384 117 (30%) 
 
76 (65%) Both trials showed improved 
SMWT in PAH treated with 
ambrisentan compared with 
placebo.  Similar benefit in SSc 
cases to overall cohort 
172 
Macitentan 
(SERAPHIN) 
Morbidity and 
mortality  
742 224  
(30%) 
NS The first event driven morbidity-
mortality trial showed that adding 
macitenan to background therapy 
150 
  
or as first line treatment was 
superior to placebo.  Umerically 
similar benefit for SSc-PAH to 
overall cohort 
PDE5 inhibitor 
Sildenafil 
(SUPER-1) 
SMWT  278 84 
(30%) 
 
38 (45%) Significant improvement in SMWT 
for sildenafil treated PAH 
compared with placebo and similar 
effect in SSc-PAH to overall cohort 
148 
Soluble guanylate cyclase agonist 
Riociguat 
(PATENT-1, and 
PATENT-2) 
SMWT  443 96 
(22%) 
 
59 (61%) Improved SMWT distance in PAH 
cases treated with riociguat 
compared with placebo, including 
those on background ERA.  
Numerically smaller gain in PAH-
SSc but good long term survival in 
all PAH 
156 
Prostacyclin pathway targeting therapies  
Epoprostenolb SMWT  111 111 
(100%) 
 
111 (100%) Open label study showed gain in 
exercise capacity (SMWT) but no 
mortality benefit.   
144,145 
Treprostinilc SMWT  470 90 
(19%) 
 
NS  Significant improvement in SMWT 
for subcutaneous treprostinil 
treated PAH compared with 
placebo and similar effect in SSc-
PAH to overall cohort 
171 
  
Iloprostc (AIR) SMWT  203 35 (17%) 
 
NS Numerical gain in SMWT in active 
treatment compared with placebo 
but not reaching statistical 
significance. 
169 
Selexipagb 
(GRIPHON) 
Morbidity and 
mortality  
1156 334 (29%)  170 (51%) Largest event driven morbidity-
mortality trial performed t date 
showed that adding selexipag to 
background therapy or as first line 
treatment was superior to placebo.  
Numerically similar benefit for SSc-
PAH to overall cohort  
151 
Combined therapy with an endothelin receptor antagonist and phosphodiesterase type 5 inhibitor  
Bosentan added 
to sildenafil 
(COMPASS-2) 
Morbidity and 
mortality  
334 NS  NS No evidence of significant benefit 
for combining sildenafil and 
bosentan compared with sildenafil 
alone 
172 
Ambrisentan and 
tadalafil 
(AMBITION) 
Morbidity and 
mortality  
500 187 (37%)  118 (63%) Important study demonstrating 
that initial combination therapy 
was superior to either single 
treatment in PAH including PAH 
due to SSc and significant benefit 
was equivalent for SSc and non-SSc 
cases including idiopathic PAH 
154 
aRange indicates separate values for ARIES-1 and ARIES-2 trials Prostacyclin pathway targeting therapies include prostacyclin agonistsb 
and synthetic prostacyclinsc. 
 
AIR, Aerosolized Iloprost Randomized; AMBITION, Ambrisentan and Tadalafil in Patients with Pulmonary Arterial Hypertension; ARIES, 
Ambrisentan in Patients with Moderate to Severe Pulmonary Arterial Hypertension; BREATHE, Bosentan: Randomised Trial of Endothelin 
  
Receptor antagonist Therapy for Pulmonary Arterial Hypertension; COMPASS, Combination Therapy in Pulmonary Arterial Hypertension; 
GRIPHON, Prostacyclin (PGI2) Receptor Agonist In Pulmonary Arterial Hypertension; NS, not specified in the trial report; PATENT, 
Pulmonary Arterial Hypertension Soluble Guanylate Cyclase–Stimulator Trial; PDE5, phosphodiesterase type 5 inhibitor; SERAPHIN, 
Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve Clinical Outcome; SMWT, six minute walk 
test; STRIDE, Sitaxsentan To Relieve Impaired Exercise in Pulmonary Arterial Hypertension; SUPER, Sildenafil Use in Pulmonary Arterial 
Hypertension 
  
  
Figure 1 Pathogenesis of major lung complications in systemic sclerosis 
Multiple cell types and mediators are probably involved in the pathogenesis of lung fibrosis and 
pulmonary arterial hypertension. Tissue damage initiated by epithelial injury or inflammation might 
result in a local environment within the lung parenchyma that results in the generation and persistence 
of myofibroblasts. Accumulation of excess extracellular matrix and destruction of the lung structure in 
the absence of repair and regeneration can most often lead to a NSIP pattern of lung disease. In the 
pulmonary circulation, endothelial damage might promote a proliferative vascular response that 
includes multiple cell types and results in endoluminal lesions and medial wall thickening. Vascular 
fibrosis and perivascular inflammation can subsequently occur. The pathogenic processes that occur 
following epithelial injury (leading to lung fibrosis) and pulmonary endothelial injury (triggering 
pulmonary arterial hypertension) seem to be shared. Hence, SSc might be a susceptibility phenotype for 
these complications and other facets of the disease process, and autoimmune, genetic or environment 
factors might determine which of the potential manifestations is predominant. 
 
Figure 2 Screening for pulmonary hypertension in systemic sclerosis 
This schematic is an example of one approach for diagnosing and screening patients with pulmonary 
hypertension, and is in line with current recommendations for the diagnosis and management of such 
patients [71,76] . All patients with systemic sclerosis (SSc) should have an initial assessment looking at 
clinical features, lung function (including measures of diffusing capacity for carbon monoxide (DLCO)) 
and transthoracic echocardiographic findings. The abundance of N-terminal pro-brain natriuretic 
peptide (Nt-pro BNP) should also be measured. For patients with a DLCO <60% and disease duration of 
>3 years, the DETECT score can be calculated [77]. These tests are repeated annually in all patients, and 
if a patient develops clinical features suggestive of possible new pulmonary hypertension these tests are 
repeated more often. If the results (from either the transthoracic echocardiographic findings, pulmonary 
function tests or DETECT score) exceed defined thresholds, right heart catheterization should be 
performed to confirm a diagnosis of pulmonary hypertension. A diagnosis of pulmonary arterial 
hypertension (PAH) requires a low pulmonary arterial wedge pressure (PAWP) and the absence of major 
lung fibrosis (which would otherwise be classified as group III pulmonary hypertension).   
FVC, forced vital capacity; mPAP, meaning resting pulmonary arterial pressure;  
 
Figure 3 Histological and CT appearances of major lung complications in systemic sclerosis 
The most common histological pattern of lung fibrosis in SSc is NSIP, which might be mild (part a) or 
extensive (part b) and is characterized by relative preservation of lung architecture and often a 
homogeneous “ground glass” change within the lungs (GC arrow).  NSIP might have cellular or fibrotic 
subtypes. By contrast, compared with NSIP, the less common UIP pattern of fibrosis (part c) has a much 
more altered architecture, a more variable severity of fibrotic lesions and a less homogeneous pattern 
with dense fibrosis and cystic changes, termed honeycombing (HC arrow). Pulmonary hypertension (part 
d) is characterized by enlargement of the pulmonary artery on CT imaging (PA arrow). A designation of 
PAH can only be made if only mild lung fibrosis is present as otherwise a classification of group III 
  
pulmonary hypertension is made. It is also important to note whether CT features of pulmonary veno-
occlusive disease (PVOD) are present such as septal lines, nodules or lymphadenopathy (not shown). 
 
Glossary terms  
Dyspnoea.  Breathlessness that is a major symptom of lung complications in systemic sclerosis but that 
also has other potential causes including cardiac disease, anaemia and deconditioning. 
Exertional dyspnoea.  Subjective breathlessness that occurs on exertion and is a cardical feature of 
significant lung complications including lung fibrosis and pulmonary hypertension. 
Fibroblasts.  Cells that produce extracellular matrix and that are activated inappropriately or excelssively 
in fibrotic disease. 
Myofibroblasts.  Activated fibroblastic cells that have a contractile cytoskeleton that includes 
microfibrils containing alpha smooth muscle actin. 
lung function test.  Collective term for the physiological measurement of lung volume, airways 
resistance and gas exchange in the lungs.  
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The two major lung complications in systemic sclerosis, lung fibrosis and pulmonary arterial 
hypertension, share some pathogenic mechanisms. Strategies for managing patients with these 
complications has greatly advanced in the past decade and many tools and treatments are now 
available. 
 
 



